Sociedad Americana de Hirudoterapia

Štátny ústav pre kontrolu liečiv — State Institute for Drug Control of Slovakia

ŠÚKL · Slovakia · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Slovakia's State Institute for Drug Control — leeches fall under EU medical-device frameworks (MDR 2017/745) as implemented through Slovak national law; leech-specific national authorisation has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Slovakia
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Slovak Act No. 362/2011 on Medicinal Products and Medical Devices
  • EU Medical Device Regulation (MDR) 2017/745 — as transposed into Slovak law
  • Slovak Act No. 578/2004 on Healthcare Providers

Prescriber Requirements

  • Slovak Medical Chamber (Slovenská lekárska komora)–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

ŠÚKL registration as applicable; Slovak-language labelling required by national law. Standard cold-chain conditions; EU intra-community movement under MDR applies.

Import/Export Rules

Free movement within the EU single market under MDR; State Veterinary and Food Administration clearance for live invertebrates from non-EU origin; CITES Appendix II paperwork for Hirudo medicinalis / verbana on extra-EU import.

Reimbursement Context

General Health Insurance Company (VšZP) and other public payers may cover inpatient bundled use; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general EU MDR framework as transposed into Slovak law. ŠÚKL coordinates with EMA and other EU NCAs; whether leech-specific guidance exists has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.